As the opioid misuse and overdose epidemic impacts communities across America and has sweeping global implications, practitioners are looking to the future of pain management and the novel treatment options that may be on the horizon.
dsuvia,
FDA,
Raeford Brown,
Opioid Therapy,
Opioid Epidemic
The Controversial Approval of Dsuvia by the Food and Drug Administration
Earlier this month on November 2nd, the U.S. Food and Drug Administration approved Dsuvia, a new sublingual version of an older drug, sufentanil, that has been in use since 1984.
Last week on the AffirmHealth Blog we discussed MIPS and PDMP Usage and promised a follow up on additional Improvement Activities. So this week we look at an Improvement Activities Data overview as well as a handful of activities potentially pertinent to providers prescribing opioids or other controlled substances.
Let’s start at the beginning…
Naloxone is a medication approved by the Food and Drug Administration (FDA) to prevent overdose by opioids it is designed to rapidly reverse opioid overdose. Commercially, it has been available for almost 50 years and several formulations are available, produced by various manufacturers.
Everyday the media is flooded with stories about the toll of opioid addiction in America. New rules and regulations are regularly being introduced on a state and national level as we collectively grapple with how to tackle this epidemic. However, the war on opioids in America is not new. In 2011, the Centers for Disease Control warned that prescription painkiller overdoses had reached what was considered “epidemic levels.”
At AffirmHealth, we’ve directed much of our blog content towards safe and responsible opioid prescribing practices with an emphasis on the application of state and federal guidelines to daily clinician activities.
Comments